肠道菌群在非小细胞肺癌中作用的研究进展

Research progress of effect of gut microbiota on non-small cell lung cancer

人类肠道微生物群调节宿主的许多病理、生理过程,包括代谢、炎症、免疫和细胞反应等。近年来,肺癌的发病率和死亡率快速上升,是现今癌症治疗领域面临的最大挑战之一,尤其是非小细胞肺癌。动物模型和临床研究发现非小细胞肺癌患者肠道菌群较健康者发生显著改变,肠道菌群及代谢物不仅可以通过调节免疫、炎症反应等发挥促癌或抑癌作用,还与非小细胞肺癌放化疗、免疫治疗的耐药性相关。因此,肠道菌群和相关代谢物既可成为非小细胞肺癌患者早期诊断和预后的潜在标志物,又可成为靶向药物的新型治疗靶点。本研究将从肠道菌群在非小细胞肺癌的最新研究进展做一综述,为非小细胞肺癌提供新的诊疗思路。

The human gut microbiota regulates many host pathophysiological processes including metabolic,inflammatory,immune and cellular responses.In recent years,the incidence and mortality of lung cancer have increased rapidly,which is one of the biggest challenges in the field of cancer treatment today,especially in non-small cell lung cancer.Animal models and clinical studies have found that the gut microbiota of non-small cell lung cancer patients is significantly changed compared with the healthy people.The gut microbiota and metabolites can not only play a procancer or tumor suppressor role by regulating immune,inflammatory responses and so on,but also be related with radiotherapy and chemotherapy of non-small cell lung cancer and the resistance of immunotherapy.Therefore,gut microbiota and related metabolites can be both potential markers for early diagnosis and prognosis in patients with nonsmall cell lung cancer and novel therapeutic targets for targeted drugs.This study will review the latest research progress of effect of gut microbiota on non-small cell lung cancer,and provide a new diagnosis and treatment ideas for non-small cell lung cancer.